Zeneca Accolate Sales Reach $88 Mil. During 1997, Firm Reports
Executive Summary
Zeneca's leukotriene receptor antagonist Accolate generated $88 mil. (pound 53 mil.) in revenues during its first full year on the market, the company reported during a March 5 press briefing in London.